Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cncure Biotech Inc. is currently navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These cases are distributed across 3 distinct art units, which suggests that the company's research is being evaluated in several different specialized biological fields. Furthermore, the prosecution involves distinct examiners, meaning that no cases are being reviewed by the same person. This distribution requires a tailored strategy for each application to account for the different perspectives of the examiners involved.
ROBERT A ZEMAN is the busiest examiner for the company, currently handling 1 pending office action. This 1 pending office action is part of the broader 3 pending office actions that make up the company's current active portfolio. The fact that there are 3 distinct art units for three cases indicates a high degree of technical diversity in the company's filings. Practitioners should be prepared to handle the specific procedural nuances of each art unit and examiner. With the busiest examiner managing a portion of the workload, the company's prosecution efforts are spread across the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
| UNDERDAHL, THANE E | 1 | 58.8% | +50.2% |
| DONOHUE, SEAN R | 1 | 41.4% | +21.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707225 | Pharmaceutical Composition Comprising Salmonella Strain and Immune Checkpoint Inhibitor as Active Ingredient for Prevention or Treatment of Cancer | ZEMAN, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707225 | Pharmaceutical Composition Comprising Salmonella Strain and Immune Checkpoint Inhibitor as Active Ingredient for Prevention or Treatment of Cancer | ZEMAN, ROBERT A | — |
| 18252268 | SALMONELLA STRAIN FOR PREVENTION AND TREATMENT OF CANCER AND USE THEREOF | UNDERDAHL, THANE E | — |
| 17491593 | COMPOSITION FOR DIAGNOSIS OF FUNGAL INFECTION | DONOHUE, SEAN R | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1699 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707225 | Pharmaceutical Composition Comprising Salmonella Strain and Immune Checkpoint Inhibitor as Active Ingredient for Prevention or Treatment of Cancer | ZEMAN, ROBERT A | 1645 | §102§112 | Non-Final OA | — | Pending | May 03, 2024 |
| 18252268 | SALMONELLA STRAIN FOR PREVENTION AND TREATMENT OF CANCER AND USE THEREOF | UNDERDAHL, THANE E | 1699 | §112 | Non-Final OA | — | Pending | May 09, 2023 |
| 17491593 | COMPOSITION FOR DIAGNOSIS OF FUNGAL INFECTION | DONOHUE, SEAN R | 1618 | §103 | Final Rejection | — | Pending | Oct 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCncure Biotech Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Robert A Zeman has the most, with 1 of Cncure Biotech Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
